Hyper Immune Globulin Market

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyper Immune Globulin Market contains market size and forecasts of Hyper Immune Globulin in global, including the following market information:

Global Hyper Immune Globulin Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Hyper Immune Globulin Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Hyper Immune Globulin companies in 2021 (%)

The global Hyper Immune Globulin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Hepatitis B Immunoglobulins Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hyper Immune Globulin include CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG and Hualan Bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Hyper Immune Globulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hyper Immune Globulin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Hyper Immune Globulin Market Segment Percentages, by Type, 2021 (%)

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Others

Global Hyper Immune Globulin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Hyper Immune Globulin Market Segment Percentages, by Application, 2021 (%)

Government Institutions

Private Sector

Others

Global Hyper Immune Globulin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Hyper Immune Globulin Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hyper Immune Globulin revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Hyper Immune Globulin revenues share in global market, 2021 (%)

Key companies Hyper Immune Globulin sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Hyper Immune Globulin sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics